Illuminating Clues of Cancer Buried in Prostate MR Image: Deep Learning and Expert Approaches.

Journal: Biomolecules
Published Date:

Abstract

Deep learning algorithms have achieved great success in cancer image classification. However, it is imperative to understand the differences between the deep learning and human approaches. Using an explainable model, we aimed to compare the deep learning-focused regions of magnetic resonance (MR) images with cancerous locations identified by radiologists and pathologists. First, 307 prostate MR images were classified using a well-established deep neural network without locational information of cancers. Subsequently, we assessed whether the deep learning-focused regions overlapped the radiologist-identified targets. Furthermore, pathologists provided histopathological diagnoses on 896 pathological images, and we compared the deep learning-focused regions with the genuine cancer locations through 3D reconstruction of pathological images. The area under the curve (AUC) for MR images classification was sufficiently high (AUC = 0.90, 95% confidence interval 0.87-0.94). Deep learning-focused regions overlapped radiologist-identified targets by 70.5% and pathologist-identified cancer locations by 72.1%. Lymphocyte aggregation and dilated prostatic ducts were observed in non-cancerous regions focused by deep learning. Deep learning algorithms can achieve highly accurate image classification without necessarily identifying radiological targets or cancer locations. Deep learning may find clues that can help a clinical diagnosis even if the cancer is not visible.

Authors

  • Jun Akatsuka
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. jun.akatsuka@riken.jp.
  • Yoichiro Yamamoto
    Department of Pathology, Shinshu University School of Medicine, Nagano, Japan.
  • Tetsuro Sekine
    Department of Radiology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. netti@nms.ac.jp.
  • Yasushi Numata
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. yasushi.numata@riken.jp.
  • Hiromu Morikawa
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. hiromu.morikawa@riken.jp.
  • Kotaro Tsutsumi
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. ktsutsum@hs.uci.edu.
  • Masato Yanagi
    Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. area-i@nms.ac.jp.
  • Yuki Endo
    Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. y-endo1@nms.ac.jp.
  • Hayato Takeda
    Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. s8053@nms.ac.jp.
  • Tatsuro Hayashi
    Media Co., Ltd., 3-26-6 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Masao Ueki
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan.
  • Gen Tamiya
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan.
  • Ichiro Maeda
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. ichiro@insti.kitasato-u.ac.jp.
  • Manabu Fukumoto
    Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan. manabu.fukumoto@riken.jp.
  • Akira Shimizu
    Department of Analytic Human Pathology, Nippon Medical School, Tokyo 113-8602, Japan. ashimizu@nms.ac.jp.
  • Toyonori Tsuzuki
    Department of Surgical Pathology, Aichi Medical University Hospital, Aichi 480-1195, Japan. tsuzuki@aichi-med-u.ac.jp.
  • Go Kimura
    Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. gokimura@nms.ac.jp.
  • Yukihiro Kondo
    Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan. kondoy@nms.ac.jp.